trifluoromethanesulfonic acid 3-phenyl-isoxazol-5-yl ester | 454253-30-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: trifluoromethanesulfonic acid 3-phenyl-isoxazol-5-yl ester
• 英文别名: 3-phenyl-5-(trifluoromethanesulfonyl)oxyizoxazole；3-phenylisoxazol-5-yl trifluoromethanesulfonate；3-Phenyl-5-trifluoromethanesulfonyloxyisoxazole；(3-Phenyl-1,2-oxazol-5-yl) trifluoromethanesulfonate
• CAS: 454253-30-6
• 化学式: C₁₀H₆F₃NO₄S
• 分子量: 293.223
• InChiKey: ZTLHRBFCMXMXIK-UHFFFAOYSA-N

物化性质

• 沸点：
  396.6±42.0 °C(Predicted)
• 密度：
  1.525±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  77.8
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  trifluoromethanesulfonic acid 3-phenyl-isoxazol-5-yl ester 生成 4-[4-(3-Phenyl-isoxazol-5-yl)-phenoxy]-phenol
  参考文献：
  名称：

  Potent, selective pyrimidinetrione-based inhibitors of MMP-13

  摘要：

  Using SAR from two related series of pyrimidinetrione-based inhibitors, compounds with potent MMP-13 inhibition and > 100-fold selectivity against other MMPs have been identified. Despite high molecular weights, c log Ps, and polar surface areas, the compounds are generally well absorbed and have excellent pharmacokinetic (PK) properties when dosed as sodium salts. In a rat fibrosis model, a compound from the series displayed no fibrosis at exposures many fold greater than its MMP-13 IC50. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.066
• 作为产物：
  描述：

  三氟甲磺酸酐 、 3-苯基-5-异噁唑酮 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.84h， 以82%的产率得到trifluoromethanesulfonic acid 3-phenyl-isoxazol-5-yl ester
  参考文献：
  名称：

  通过亲核取代和钯催化的交叉偶联策略将异恶唑-5-酮转化为3,5-二取代的异恶唑的通用平台

  摘要：

  通过两步策略，已经开发出了将异恶唑-5-酮转化为3,5-二取代异恶唑的通用平台。第一步导致5-（假）卤代异恶唑的形成，而第二步则可以通过亲核取代或钯安装各种杂烷基链，杂芳基链，烷基链，烯基链，炔基链和芳基链催化的交叉偶联反应。

  DOI：

  10.1002/ejoc.201900187

文献信息

• Sonogashira Coupling of Functionalized Trifloyl Oxazoles and Thiazoles with Terminal Alkynes:  Synthesis of Disubstituted Heterocycles
  作者：Neil F. Langille、Les A. Dakin、James S. Panek

  DOI：10.1021/ol026099r

  日期：2002.7.1

  see text] This paper describes Sonogashira cross-coupling of functionalized 2-, 4-, and 5-trifloyl oxazoles and thiazoles with terminal alkynes. This methodology has been extended to 2,4-ditrifloylthiazoles, which results in regioselective cross-coupling at the C2-position of the thiazole. The resulting 2-alkynyl-4-trifloylthiazoles are effective electrophiles in a second palladium(0)-mediated cross-coupling

  [反应：参见正文]本文描述了功能化的2-，4-和5-三氟甲恶唑和噻唑与末端炔烃的Sonogashira交叉偶联。该方法已经扩展到2,4-二甲苯基噻唑，这导致在噻唑的C2位区域选择性交叉偶联。在第二个钯（0）介导的交叉偶联反应中，所得的2-炔基-4-三氟噻唑是有效的亲电子试剂。
• Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
  申请人：——

  公开号：US20040006057A1

  公开（公告）日：2004-01-08

  The present invention relates to triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione; metalloproteinase inhibitors of the formula 1 wherein X, A, Y, B, G, W, and R 1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.

  本发明涉及三芳基氧基吡啶二酮类金属蛋白酶抑制剂，其化学式为1，其中X、A、Y、B、G、W和R1如规范中所定义，并涉及用于治疗炎症、癌症和其他疾病的药物组合物和方法。
• TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1501515B1

  公开（公告）日：2005-11-02
• US7119201B2
  申请人：——

  公开号：US7119201B2

  公开（公告）日：2006-10-10
• [EN] TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEINASE TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE
  申请人：PFIZER PROD INC

  公开号：WO2003090752A1

  公开（公告）日：2003-11-06

  The present invention relates to triaryl-oxy-aryloxy-pyrimidine-2,4.6-trione; metalloproteinase inhibitors of the formula wherein X, A, Y, B, G, W. and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.